Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyondIII기 NSCLC 환자를 위한 2주 및 4주 보조제 durvalumab의 안전성 모니터링: COVID-19 범유행 및 그 이후에 미치는 영향Article Published on 2021-06-012022-09-12 Journal: Lung cancer (Amsterdam, Netherlands) [Category] MERS, SARS, 진단, [키워드] adjuvant Adjuvant durvalumab analysed approved Autoimmune disease blood tests Cancer carried clinical COVID-19 COVID-19 pandemic durvalumab hospital Immunotherapy implication NSCLC. observé pandemic Patient patients treated receiving Retrospective study risk factor Safety SARS-CoV-2 stage III Support survival toxicities Toxicity treated two groups [DOI] 10.1016/j.lungcan.2021.04.021 PMC 바로가기 [Article Type] Article